<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835584</url>
  </required_header>
  <id_info>
    <org_study_id>KRT-232-117</org_study_id>
    <nct_id>NCT04835584</nct_id>
  </id_info>
  <brief_title>KRT-232 and TKI Study in Chronic Myeloid Leukemia</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kartos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kartos Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the&#xD;
      treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are&#xD;
      refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI).&#xD;
&#xD;
      This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232&#xD;
      in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed&#xD;
      TKI treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Maximum tolerated dose (MTD)/maximum administered dose (MAD) of KRT-232</measure>
    <time_frame>28 Days</time_frame>
    <description>DLTs will be used to establish the MTD/MAD of KRT-232 in combination with dasatinib or nilotinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, Arm A and B: Major cytogenetic response (MCyR) rate</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of subjects who achieved complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR) according to modified ELN criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, Arm C: Major hematological response (MaHR) rate</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of subjects who achieved MaHR according to modified ELN criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MCyR rate</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of subjects who achieved CCyR or PCyR according to modified ELN criteria in Arms A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCyR rate</measure>
    <time_frame>47 months</time_frame>
    <description>The proportion of subjects who achieved CCyR or PCyR according to modified ELN criteria in Arm C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>47 months</time_frame>
    <description>DOR (Kaplan-Meier estimate) defined as the time from first observation of response to progression/relapse or death, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete hematologic response (CHR)</measure>
    <time_frame>47 months</time_frame>
    <description>The proportion of subjects who achieve a CHR according to modified ELN criteria in Arms A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) in each Arm</measure>
    <time_frame>47 months</time_frame>
    <description>PFS is defined as the time from the first treatment dose date to progression/relapse or death, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in each Arm</measure>
    <time_frame>47 months</time_frame>
    <description>OS is defined as the time from the first treatment dose date to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">133</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. TKI (dasatinib or nilotinib) will be administered orally, per locally prescribed dose and schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Arm A (KRT-232 combined with Dasatinib in patients with CML-CP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasastinib will be administered orally, per locally prescribed dose and schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Arm B (KRT-232 combined with Nilotinib in patients with CML-CP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Nilotinib will be administered orally, per locally prescribed dose and schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasatinib or Nilotinib will be administered orally, per locally prescribed dose and schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRT-232</intervention_name>
    <description>KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.</description>
    <arm_group_label>Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP</arm_group_label>
    <arm_group_label>Part 2, Arm A (KRT-232 combined with Dasatinib in patients with CML-CP)</arm_group_label>
    <arm_group_label>Part 2, Arm B (KRT-232 combined with Nilotinib in patients with CML-CP)</arm_group_label>
    <arm_group_label>Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.</description>
    <arm_group_label>Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP</arm_group_label>
    <arm_group_label>Part 2, Arm A (KRT-232 combined with Dasatinib in patients with CML-CP)</arm_group_label>
    <arm_group_label>Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)</arm_group_label>
    <other_name>Dasatinib Zentiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.</description>
    <arm_group_label>Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP</arm_group_label>
    <arm_group_label>Part 2, Arm B (KRT-232 combined with Nilotinib in patients with CML-CP)</arm_group_label>
    <arm_group_label>Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)</arm_group_label>
    <other_name>Tasigna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Phase 1b and Phase 2 Arms A and B: Documented TP53wt, Ph+, BCR-ABL+ CML-CP&#xD;
&#xD;
          -  Phase 2 Arm C ONLY: Documented TP53wt, Ph+, BCR-ABL+ CML-AP&#xD;
&#xD;
          -  Subject is resistant (relapsed or refractory) and/or intolerant to at least 2 prior&#xD;
             TKIs.&#xD;
&#xD;
          -  Adults ≥ 18 years of age.&#xD;
&#xD;
          -  ECOG performance status of 0 to 2&#xD;
&#xD;
          -  Adequate hematologic, hepatic, and renal functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Phase 1b and Phase 2 Arms A and B: Documented Ph+, BCR-ABL+ CML-AP&#xD;
&#xD;
          -  Documented Ph+, BCR-ABL+ CML-BC&#xD;
&#xD;
          -  Known history of T315I mutation.&#xD;
&#xD;
          -  Prior treatment with MDM2 antagonist therapies.&#xD;
&#xD;
          -  Intolerance to current TKI therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Mei</last_name>
    <phone>650-542-0136</phone>
    <email>jmei@kartosthera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Houlihan</last_name>
    <phone>650-839-7293</phone>
    <email>ehoulihan@kartosthera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pratia Onkologia Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Madrid</city>
        <state>Navarra</state>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>navtemadlin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

